Stratophase Heads £1.2m Project to Develop Real-Time High Value Liquid Monitoring Systems
News Mar 10, 2010
Stratophase has announced at Pittcon that, as part of a consortium of companies, it is developing a cost-effective, multi-parametric, multi-point, in-line sensor system for high-value liquid production processes.
Utilizing Stratophase’s advanced SpectroSens optical microchip technology, this £1.2m project will initially tackle complex production processes, such as those associated with active pharmaceutical ingredients (API) and butanol-based biofuels. Highly accurate, real-time and data-rich ‘fingerprints’ of the various manufacturing stages will be produced to enable tighter and timely control, which will minimize waste and increase yields.
Dr Richard Williams, CEO of Stratophase commented, “Our existing SpectroSens technology has already been successfully demonstrated in a range of different processes including fermentations and continuous flow reactions. We are delighted to have the opportunity to build on this success with this new project.”
Stratophase’s patented SpectroSens technology is developed to provide an intrinsically safe, passive and spark-free system for the in-line monitoring of liquids throughout the complete manufacturing process.
At present the technology monitors liquids based on measurements associated with temperature and refractive index. This project aims to expand the SpectroSens technology, by focusing on developing additional measurement parameters such as spectroscopic information, particle content, pressure and viscosity, to provide multiple measurements at each point of the process. This will enable real-time monitoring of key criteria, and employ Quality by Design (QBD) principles to fulfill Process Analytical Technology (PAT) requirements. The data will be available at each stage of a process, making it simple to identify any potential problems as they occur, for cost-effective production.
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Cell-weighing Method Could Help Doctors Choose Cancer DrugsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE